TVGN · Tevogen Inc. · Financials
Market Cap
$47.92M
Shares
6.51M
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Net Income
-$26.28M
-91.4%
FY2025
Diluted EPS
-$8.08
-130.9%
FY2025
Operating Cash Flow
-$12.33M
-2.7%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| -$302.57K | -$195.62K | -$184.04K | — | — | |
| $11.63M | $11.11M | $31.03M | $4.4M | — | |
| $9.77M | $15.03M | $22.53M | $4.44M | $953.08K | |
| $21.4M | $26.14M | $53.56M | $8.84M | — | |
| $29.47M | — | — | $2.27M | $953.08K | |
| -$21.4M | -$26.14M | -$53.56M | -$8.84M | — | |
| — | — | $184.04K | $1.21M | — | |
| — | — | — | $2.73M | $4.95M | |
| — | — | — | $2.21M | $5.36M | |
| — | $4750 | $1750 | — | — | |
| -$21.61M | -$26.28M | -$13.73M | -$60.48M | $4.41M | |
| -$22.14M | -$26.83M | -$10.27M | -$60.48M | — | |
| USD/shares | -$6.25 | -$8.08 | -$3.50 | -$122.00 | — |
| USD/shares | -$6.25 | -$8.08 | -$3.50 | -$122.00 | — |
| shares | — | 3.32M | 2.93M | 495.04K | — |
| shares | — | 3.32M | 2.93M | 495.04K | — |
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Debt Profile
Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Debt data is being processed. Please check back later.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 5.41×
EV/EBIT
—
Peer median 12.38×
P/E (TTM)
—
Peer median 4.06×
Peer medians compare against the 281 similar-size Biotechnology companies (of 536 listed).